The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world study of the treatments following trastuzumab-emtansine for HER2-positive metastatic breast cancer: A multicentral cohort study (WJOG12519B).
 
Sasagu Kurozumi
No Relationships to Disclose
 
Takamichi Yokoe
Honoraria - Eisai; Kiowa Kirin; Pfizer
 
Kazuki Nozawa
No Relationships to Disclose
 
Yukinori Ozaki
Honoraria - Chugai Pharma
 
Tetsuyo Maeda
No Relationships to Disclose
 
Shu Yazaki
No Relationships to Disclose
 
Mai Onishi
No Relationships to Disclose
 
Akihiro Fujimoto
No Relationships to Disclose
 
Sayuka Nakayama
No Relationships to Disclose
 
Yuko Tsuboguchi
No Relationships to Disclose
 
Tsutomu Iwasa
No Relationships to Disclose
 
Hitomi Sakai
No Relationships to Disclose
 
Misato Ogata
No Relationships to Disclose
 
Mitsuo Terada
No Relationships to Disclose
 
Meiko Nishimura
No Relationships to Disclose
 
Takuma Onoe
Honoraria - Bristol-Myers Squibb
 
Jun Masuda
No Relationships to Disclose
 
Michiko Kurikawa
No Relationships to Disclose
 
Mototsugu Shimokawa
Consulting or Advisory Role - Sysmex
 
Toshimi Takano
Honoraria - Celltrion; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)